Daniel R. Saltzstein

3.4k total citations · 1 hit paper
87 papers, 2.0k citations indexed

About

Daniel R. Saltzstein is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Daniel R. Saltzstein has authored 87 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 21 papers in Surgery and 20 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Daniel R. Saltzstein's work include Prostate Cancer Treatment and Research (47 papers), Hormonal and reproductive studies (20 papers) and Bladder and Urothelial Cancer Treatments (19 papers). Daniel R. Saltzstein is often cited by papers focused on Prostate Cancer Treatment and Research (47 papers), Hormonal and reproductive studies (20 papers) and Bladder and Urothelial Cancer Treatments (19 papers). Daniel R. Saltzstein collaborates with scholars based in United States, Canada and France. Daniel R. Saltzstein's co-authors include Rodney U. Anderson, Neal D. Shore, Norman R. Zinner, Roger R. Dmochowski, Jeanette S. Brown, Bruce Blank, Jacques G. Susset, Rodney A. Appell, Ronald Tutrone and Fred Saad and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Daniel R. Saltzstein

77 papers receiving 1.9k citations

Hit Papers

Oral Relugolix for Androgen-Deprivation Therapy in Advanc... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
    2020 259 citations Neal D. Shore, Fred Saad et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel R. Saltzstein United States 20 749 720 654 514 318 87 2.0k
Paul Sieber United States 27 327 0.4× 357 0.5× 1.3k 2.0× 174 0.3× 319 1.0× 75 2.3k
Seiichiro Ozono Japan 35 906 1.2× 506 0.7× 1.4k 2.1× 430 0.8× 930 2.9× 207 3.5k
Jong Jin Oh South Korea 21 415 0.6× 371 0.5× 836 1.3× 161 0.3× 455 1.4× 146 1.6k
J. Atkins United States 12 349 0.5× 166 0.2× 1.4k 2.1× 118 0.2× 285 0.9× 19 2.3k
Fritz H. Schroeder Netherlands 29 358 0.5× 353 0.5× 1.4k 2.2× 74 0.1× 446 1.4× 63 2.4k
Ming‐Kuen Lai Taiwan 24 190 0.3× 92 0.1× 512 0.8× 191 0.4× 512 1.6× 80 1.9k
Savio Domenico Pandolfo Italy 24 200 0.3× 106 0.1× 746 1.1× 178 0.3× 396 1.2× 92 1.5k
Shingo Hatakeyama Japan 22 282 0.4× 112 0.2× 523 0.8× 81 0.2× 664 2.1× 176 1.8k
Noboru Hara Japan 20 104 0.1× 191 0.3× 615 0.9× 100 0.2× 302 0.9× 106 1.4k
Hung‐Lung Ke Taiwan 25 214 0.3× 67 0.1× 473 0.7× 107 0.2× 892 2.8× 121 1.8k

Countries citing papers authored by Daniel R. Saltzstein

Since Specialization
Citations

This map shows the geographic impact of Daniel R. Saltzstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel R. Saltzstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel R. Saltzstein more than expected).

Fields of papers citing papers by Daniel R. Saltzstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel R. Saltzstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel R. Saltzstein. The network helps show where Daniel R. Saltzstein may publish in the future.

Co-authorship network of co-authors of Daniel R. Saltzstein

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel R. Saltzstein. A scholar is included among the top collaborators of Daniel R. Saltzstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel R. Saltzstein. Daniel R. Saltzstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shore, Neal D., Daniel R. Saltzstein, Yaron Ehrlich, et al.. (2025). Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study. Clinical Genitourinary Cancer. 23(5). 102392–102392.
2.
Spratt, Daniel E., Daniel J. George, Neal D. Shore, et al.. (2024). Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. JAMA Oncology. 10(5). 594–594. 4 indexed citations
3.
Shore, Neal D., Jason Hafron, Daniel R. Saltzstein, et al.. (2024). Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP). The Journal of Urology. 212(5). 682–691. 2 indexed citations
4.
Nordquist, Luke T., Daniel R. Saltzstein, David Josephson, et al.. (2024). COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.. Journal of Clinical Oncology. 42(16_suppl). 5100–5100. 1 indexed citations
5.
Bailey, Howard H., Cameron O. Scarlett, Thomas C. Havighurst, et al.. (2024). Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery. Cancer Prevention Research. 18(1). 31–39. 1 indexed citations
6.
Shore, Neal D., Jason Hafron, Daniel R. Saltzstein, et al.. (2024). Impact of a rash management guide on incidence and severity of rash with apalutamide: Experience from the Apa-RP study in high-risk localized prostate cancer.. Journal of Clinical Oncology. 42(4_suppl). 316–316. 1 indexed citations
7.
Fleshner, Neil, Yair Lotan, Brant A. Inman, et al.. (2024). CONSISTENT PERFORMANCE OF BLADDER EPICHECK FOR NMIBC SURVEILLANCE IN THE USA AND EUROPEAN PIVOTAL STUDIES AND IN REAL WORLD STUDIES. Urologic Oncology Seminars and Original Investigations. 42. S63–S63.
8.
9.
Kulkarni, Girish S., Kyle A. Richards, Peter C. Black, et al.. (2023). MP63-01 AN INTERIM ANALYSIS OF A PHASE II CLINICAL STUDY OF INTRAVESICAL PHOTO DYNAMIC THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS). The Journal of Urology. 209(Supplement 4). 3 indexed citations
10.
Tutrone, Ronald, Fred Saad, Daniel J. George, et al.. (2023). Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. European Urology Oncology. 7(4). 906–913. 6 indexed citations
11.
Shore, Neal D., Christopher Pieczonka, Ralph J. Henderson, et al.. (2023). Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer. Urologic Oncology Seminars and Original Investigations. 41(11). 454.e9–454.e16. 2 indexed citations
12.
Markowski, Mark C., Ronald Tutrone, Christopher Pieczonka, et al.. (2022). A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent. Clinical Cancer Research. 28(13). 2789–2795. 28 indexed citations
13.
Dreicer, Robert, Franklin Chu, Robert H. Getzenberg, et al.. (2022). Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castrate resistant prostate cancer who have progressed on an androgen receptor targeting agent.. Journal of Clinical Oncology. 40(6_suppl). TPS217–TPS217. 1 indexed citations
14.
Markowski, Mark C., Ronald Tutrone, Mario A. Eisenberger, et al.. (2021). VERU-111, an oral cytoskeleton disruptor, to treat men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.. Journal of Clinical Oncology. 39(15_suppl). 5056–5056. 1 indexed citations
15.
16.
Markowski, Mark C., Mario A. Eisenberger, Ronald Tutrone, et al.. (2021). Clinical study of VERU-111, an oral cytoskeletal disruptor, in metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.. Journal of Clinical Oncology. 39(6_suppl). 131–131. 4 indexed citations
17.
Jarrard, David F., Wei Huang, KyungMann Kim, et al.. (2020). A phase II randomized placebo‐controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance. The Prostate. 81(1). 41–49. 24 indexed citations
18.
Shore, Neal D., Christopher Pieczonka, Ralph J. Henderson, et al.. (2020). Development and evaluation of the MiCheck test for aggressive prostate cancer. Urologic Oncology Seminars and Original Investigations. 38(8). 683.e11–683.e18. 4 indexed citations
19.
Saltzstein, Daniel R., et al.. (2007). Complicated Urinary Tract Infections Treated with Extended-Release Ciprofloxacin with Emphasis onPseudomonas aeruginosa. Journal of Chemotherapy. 19(6). 694–702. 4 indexed citations
20.
Messing, Edward M., Kyung Mann Kim, Francis E. Sharkey, et al.. (2006). Randomized Prospective Phase III Trial of Difluoromethylornithine vs Placebo in Preventing Recurrence of Completely Resected Low Risk Superficial Bladder Cancer. The Journal of Urology. 176(2). 500–504. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Sieber Breakdown of academic impact, for papers by Seiichiro Ozono Breakdown of academic impact, for papers by Jong Jin Oh Breakdown of academic impact, for papers by J. Atkins Breakdown of academic impact, for papers by Fritz H. Schroeder Breakdown of academic impact, for papers by Ming‐Kuen Lai Breakdown of academic impact, for papers by Savio Domenico Pandolfo Breakdown of academic impact, for papers by Shingo Hatakeyama Breakdown of academic impact, for papers by Noboru Hara Breakdown of academic impact, for papers by Hung‐Lung Ke
Rankless by CCL
2026